Boris Mankovsky

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Adrian F. Hernandez, Jennifer B. Green, Salim Janmohamed et al. · The Lancet · 2018 · 1.8K citations · Full text

Medicine, Cardiology, Pharmacotherapy +17

Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk

Aruna D. Pradhan, Robert J. Glynn, Jean‐Charles Fruchart et al. · New England Journal of Medicine · 2022 · 711 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings

David C. Klonoff, Jing Wang, David Rodbard et al. · Journal of Diabetes Science and Technology · 2022 · 276 citations · Full text

Medicine, Endocrinology, Internal Medicine +17

Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial

Deepak L. Bhatt, Philippe Gabríel Steg, Shamir R Mehta et al. · The Lancet · 2019 · 210 citations · Full text

Medicine, Cardiology, Pharmacotherapy +15

Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes

Guntram Schernthaner, Naim Shehadeh, Anna Bazarova et al. · Cardiovascular Diabetology · 2020 · 160 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17